Abstract | BACKGROUND:
Everolimus-eluting stent (EES) are considered to have better clinical outcomes than other rapamycin derivative-eluting stents; however, the individual trials may not have sufficient power to prove it. This meta-analysis aimed to compare clinical outcomes of EES against other rapamycin derivative-eluting stents. METHODS: RESULTS: We identified 16 randomized controlled trials with 23,481 patients and a weighted mean follow-up of 18 months. Compared with other rapamycin derivative-eluting stents, EES were associated with a significant reduction in definite ST [relative risk (RR): 0.45; 95% confidence interval (CI): 0.30-0.69; p<0.001] and TLR (RR: 0.87; 95% CI: 0.77-0.99; p=0.03). EES also showed a non-significant trend toward reduction in definite/probable ST (RR: 0.75; 95% CI: 0.56-1.01; p=0.06). However, both groups had similar rates of mortality (RR: 0.95; 95% CI: 0.82-1.09; p=0.45), MI (RR: 0.95; 95% CI: 0.82-1.10; p=0.43), and MACE (RR: 0.94; 95% CI: 0.87-1.02; p=0.35). The stratified analysis of the included trials showed that EES was associated with significantly lower rate of definite ST compared with either zotarolimus-eluting stent (p=0.012) or sirolimus-eluting stent (p=0.006), but not biolimus-eluting stent (p=0.16). In longer follow-up (>1 year) stratification, EES was associated with a significant reduction in risk of definite ST (p<0.001). CONCLUSIONS:
|
Authors | Yao-Jun Zhang, Lin-Lin Zhu, Christos V Bourantas, Javaid Iqbal, Sheng-Jie Dong, Carlos M Campos, Ming-Hui Li, Fei Ye, Nai-Liang Tian, Hector M Garcia-Garcia, Patrick W Serruys, Shao-Liang Chen |
Journal | Journal of cardiology
(J Cardiol)
Vol. 64
Issue 3
Pg. 185-93
(Sep 2014)
ISSN: 1876-4738 [Electronic] Netherlands |
PMID | 24560821
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Aged
- Coronary Artery Disease
(surgery)
- Databases, Bibliographic
- Drug-Eluting Stents
(adverse effects)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Myocardial Revascularization
(statistics & numerical data)
- Percutaneous Coronary Intervention
- Randomized Controlled Trials as Topic
- Sirolimus
(administration & dosage, analogs & derivatives)
- Thrombosis
(etiology, prevention & control)
- Treatment Outcome
|